Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku — Clinical Trial Site

64 Registered trials

32 Currently recruiting

Organisation

Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku

Location

Bialystok, Poland

Identifier

ORG-100044047

Address

Ul. Ogrodowa 12, 15-027, Poland

Departments

"Oddział Onkologii Klinicznej im. Dr Ewy Pileckiej"
5702:Oddzial Onkologii Ginekologicznej
Department of Medical Oncology with a Day Care Unit
Department of Medical Oncology with Day Unit
N/A
NA
Oddzial Ginekologii Onkologicznej
Oddzial Onkologii Ginekologicznej
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej im. Dr Ewy Pileckiej
Oddzial Onkologii Klinicznej Im. Dr Ewy Pileckiej z Pododzialem Chemioterapii Dziennej
Oddzial Radioterapii
Oddział Oncologic Ginekologicznej
Oddział Onkologii Ginekologicznej
Oddział Onkologii Ginekologicznej - Gynaecological Cancer Unit
Oddział Onkologii Ginekologicznej Gynaecological Cancer Unit
Oddział Onkologii Ginekologicznej oraz Poradnia Ginekologii Onkologicznej
Oddział Onkologii Ginekologicznej-Gynaecological Cancer Unit
Oddział Onkologii Klinicznej
Oddział Onkologii Klinicznej im. Dr E. Pileckiej z Pdooddziałem. Chemioterapii Dziennej
Oddział Onkologii Klinicznej im. dr E. Pileckiej z pododdziałem Chemioterapii Dziennej
Oddział onkologii klinicznej im. dr Ewy Pileckiej
Oddział onkologii klinicznej im. dr Ewy Pileckiej z pododdziałem chemioterapii dziennej
Oddział Onkologii Klinicznej im. Dr Ewy Pilickiej z Pododziałem Chemioterapii Dziennej
Oddział onkologii klinicznej z pododdziałem chemioterapii dziennej
Oddział Radioterapii I
Odzial Onkologii Klinicznej im. Dr E. Pileckiej
Oncology
Zakład Radioterapii z Pracownią Brachyterapii HDR

Clinical trials at this site (64)

Search interface

Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 5 2024-07-02
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Phase II study evaluating the efficacy of Nivolumab in the treatment of patients with nasopharyngeal cancer who progressed during or after p… Recruiting

2024-517479-19-00 Nasopharyngeal Cancer 4 2021-08-26
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Melanoma 5 2023-10-06
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended

2023-506361-56-00 Endometrial cancer 5 2022-04-01
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended

2023-505210-18-00 Early stage HER2-positive breast cancer (T stage >= T3, 5 2021-12-17
Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended

2023-506177-35-00 Ovarian, fallopian tube, or primary peritoneal carcinom 11 2021-10-23
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13